Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

  title={Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis},
  author={Niels C Pedersen and Yunjeong Kim and Hongwei Liu and Anushka C Galasiti Kankanamalage and Chrissy D Eckstrand and William C. Groutas and Michael J Bannasch and Juliana M Meadows and Kyeong-Ok Chang},
  journal={Journal of Feline Medicine and Surgery},
  pages={378 - 392}
Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP. [] Key Method Results Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks.

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

GS-441524 was shown to be a safe and effective treatment for FIP and the optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.

Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524

Oral treatment with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse effects and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species.


It was concluded that GS-441524 (5 mg/kg/day, SC) has been proven to be beneficial for improving clinical, laboratory findings and animal welfare, however, it was evaluated that clinical studies involving more cases are required in order to determine the clinical efficacy of nucleoside analogues.

Retrospective Survival Analysis of Cats with Feline Infectious Peritonitis Treated with Polyprenyl Immunostimulant That Survived over 365 Days

This study shows that PI is beneficial in the treatment of FIP, and more studies are needed to establish the best protocols of use.

Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats

An update on the current status of therapeutics for FIP is provided and due to interest in coronaviruses resulting from the current human pandemic, this review provides information on domesticated cats identified as SARS-CoV-2 positive.

Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis

Moderate evidence is provided in support of the application of GS-441524 or GC376 to extend the survival time of cats suffering from feline infectious peritonitis but more robust evidence should be obtained through well-designed randomised controlled trials.

In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus

When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group, however, the number of animals with FIP is too low to establish anti-viral effect of U18 666A in cats.

Alpha-1 Acid Glycoprotein Reduction Differentiated Recovery from Remission in a Small Cohort of Cats Treated for Feline Infectious Peritonitis

A sustained return to normal levels of AGP was the most rapid and consistent indicator for differentiating recovery from remission following treatment for FIP, and provides a useful model for differentiates recovery from chronic coronavirus disease using acute phase protein monitoring.

Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

The combined use of adalimumab and ICZ showed a therapeutic effect for experimentally induced FIP and are considered to be a treatment option until effective anti-FIPV drugs become available.

Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis

In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP, however, further investigation of a possible role of itraconsazole in FIP treatment is warranted.



An update on feline infectious peritonitis: Virology and immunopathogenesis

Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis

Pathogenesis of feline enteric coronavirus infection

Diagnostic Features of Clinical Neurologic Feline Infectious Peritonitis

Most cats with neurologic and ocular forms of FIP had patchy, focal lesions, suggesting that recently developed technologies described in this report may be useful for evaluation of cats with suspected FIP.

Broad-Spectrum Inhibitors against 3C-Like Proteases of Feline Coronaviruses and Feline Caliciviruses

The results suggest that the series of 3CLpro inhibitors described here may have the potential to be further developed as therapeutic agents against these important viruses in domestic and wild cats and provide the first insight into a structural platform for anti-FIPV and anti-FCV drug development.

A review of feline infectious peritonitis virus infection: 1963–2008

  • N. Pedersen
  • Biology, Medicine
    Journal of Feline Medicine & Surgery
  • 2009

Glial response in the central nervous system of cats with feline infectious peritonitis

A strong astrocytic response is indicated, including the presence of many less differentiated vimentin-positiveAstrocytes and gitter cells positive for RCA-1 in severe lesions in the CNS of cats with FIP.

Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

It is found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated, and results indicate that continuous virus replication is required for progression of immune-mediated inflammatory disease of FIP.